Pilling, where products ball up on the skin during application, often indicates incompatibility between formulation bases rather than active ingredient conflict
Evidence for a role of chloroplastic m-type thioredoxins in the biogenesis of photosystem II in Arabidopsis
The most common effects are mild nausea, upset stomach, bloating, and changes in bowel habits, especially when starting or raising the dose
& Edwards, R
Category : HUMAN PRESCRIPTION DRUG LABEL DEA Schedule : none Marketing Status : New Drug Application INGREDIENTS AND APPEARANCE LABELER - Hikma Pharmaceuticals USA Inc.(001230762) PRINCIPAL DISPLAY PANEL NDC 0143-9621-01 1 mL Vial Cyanocobalamin Injection, USP Rx only 1,000 mcg/mL For IM or SC use ONLY Protect from light Contains Benzyl Alcohol NDC 0143-9621-25 Rx only Cyanocobalamin Injection, USP 1,000 mcg/mL For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 25 x 1 mL Vials PRINCIPAL DISPLAY PANEL NDC 0143-9620-01 10 mL Multiple Dose Vial Cyanocobalamin Injection, USP Rx only 10,000 mcg per 10 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative NDC 0143-9620-10 Rx only Cyanocobalamin Injection, USP 10,000 mcg per 10 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 10 x 10 mL Multiple Dose Vials PRINCIPAL DISPLAY PANEL NDC 0143-9619-01 30 mL Multiple Dose Vial Cyanocobalamin Injection, USP Rx only 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative NDC 0143-9619-10 Rx only Cyanocobalamin Injection, USP 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 10 x 30 mL Multiple Dose Vials NDC 0143-9619-01 Rx only Cyanocobalamin Injection, USP 30,000 mcg per 30 mL (1,000 mcg/mL) For Intramuscular or Subcutaneous use ONLY Contains Benzyl Alcohol as a Preservative 1 x 30 mL Multiple Dose Vials PRINCIPAL DISPLAY PANEL
For example, in G6PD-deficient individuals, residual hepatic enzyme activity can prove insufficient in stress states where increased G6PD activity is required, as in neonates with comorbid G6PD deficiency and Gilberts syndrome, who are at increased risk for hyperbilirubinemia (96, 97)
